Aerial view of the Denver skyline

The Barbara Davis Center is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Peter Gottlieb, MD, the TrialNet team at the Barbara Davis Center is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.  

Our Team

Portrait photo

Peter Gottlieb, MD

Dr. Gottlieb’s research focuses on understanding the cause of autoimmunity which leads to type 1 diabetes and other related diseases.  He has focused on learning about different components of the immune system which may contribute to disease development.  As a logical extension of this basic science work, he has been involved in clinical trials in prediabetes and new and recent onset type 1 diabetes patients for 15 years.  He has been the principal investigator in investigator-initiated as well as multicenter trials and participates in trial networks such as Type 1 Diabetes TrialNet.

Portrait photo

Andrea Steck, MD

Dr. Steck’s primary research focus is in the area of epidemiology, prediction and prevention of type 1 diabetes. She has a background in pediatric endocrinology, with specific training and expertise in pediatric diabetes. Her research projects include epidemiological studies such as DAISY (Diabetes Autoimmunity Study in the Young), TEDDY (The Environmental Determinants of Diabetes in the Young), the Twin Family and TrialNet studies.

Portrait photo

Aaron Michels, MD

Dr. Michels laboratory at the Barbara Davis Center for Diabetes is focused on studying the immunology of autoimmune diseases, with a particular focus on type 1 diabetes. Having lived with type 1 diabetes for the more than 20 years, it is Dr. Michels career goal to contribute to the prevention and ultimately a cure for the disease. 
Currently, type 1 diabetes is a predictable disease with the measurement of antibodies directed against proteins from the beta cell; however it is not yet a preventable disease. His basic and translational research focuses on understanding the underlying immunology of diabetes and how human leukocyte antigen alleles confer disease risk and protection. 

Kimber Simmons

Kimber Simmons, MD

Dr. Simmons joined the faculty in 2016 as a physician scientist studying the clinical immunology of autoimmune disease, with a focus on type 1 diabetes. Her current research interests are to screen children in the general population for islet autoantibodies (early T1D), hone techniques to study the immune cells that participate in the pathogenesis of T1D and participate as an investigator in prevention trials with the goal of finding an intervention that can modulate the autoimmune attack in the pancreas. She has received a JDRF Career Development Award, and K12 award to support this work. She is also an investigator of the Autoimmunity Screening for Kids program and of Type 1 Diabetes TrialNet with a specific interest in following patients who are enrolled in immune prevention trials.

Portrait photo

Hali Broncucia

Team Manager
Portrait photo

Mara Kinney

Regulatory Manager
Portrait photo

Brenda Bradfield, RN

Research Coordinator
Portrait photo

Lexie Chesshir, RN

Research Coordinator
Portrait photo

Rob Long

Research Coordinator
Portrait photo

Soňa Seligova

Research Coordinator
Jen Albery, RN, BS

Jen Albery, RN, BS

Regional Affiliates

Washington University
660 S. Euclid , St. Louis, 63110 United States
University of Utah
50 N Medical Drive SOM Room 2B127, Salt Lake City, 84132 United States

Research Studies

Risk Screening Risk Screening

If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More

Monitoring Monitoring

Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More

Prevention Study Abatacept Prevention Study

TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 or stage 2), and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression. Details

Prevention Study Hydroxychloroquine (HCQ)

We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D. Details

Long Term Longterm Follow-up

If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More